Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › venetoclax

venetoclax

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of venetoclax

39 trials tracked of venetoclax: 12 in phase 3 or 4 and 10 with published results. The most-cited published study has 750 citations.

39Trials tracked
12Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 3 12 Phase 2 23 Phase 1 4
  1. Phase 3 A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy Completed · 750 cited
  2. Phase 3 A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy Completed · 400 cited
  3. Phase 3 A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Completed · 300 cited
  4. Phase 3 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy Completed · 143 cited
  5. Phase 3 Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia Completed · 117 cited
  6. Phase 3 Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) Completed · 49 cited
Show 33 more trials
  1. Phase 3 A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Completed · 40 cited
  2. Phase 3 A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy Completed · 15 cited
  3. Phase 3 A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). Completed · 14 cited
  4. Phase 3 A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Completed · 10 cited
  5. Phase 3 A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Completed
  6. Phase 3 A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation Completed
  7. Phase 2 Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Completed
  8. Phase 2 OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia Completed
  9. Phase 2 A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL Completed
  10. Phase 2 A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia Completed
  11. Phase 2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Completed
  12. Phase 2 Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi Completed
  13. Phase 2 A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia Completed
  14. Phase 2 Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL Completed
  15. Phase 2 Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia Completed
  16. Phase 2 Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age Completed
  17. Phase 2 Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome Completed
  18. Phase 2 A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy Completed
  19. Phase 2 A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma Completed
  20. Phase 2 Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Completed
  21. Phase 2 Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) Completed
  22. Phase 2 A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL) Completed
  23. Phase 2 Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma Completed
  24. Phase 2 A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy Completed
  25. Phase 2 Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma Completed
  26. Phase 2 Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia Completed
  27. Phase 2 Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma Completed
  28. Phase 2 Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma Completed
  29. Phase 2 A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Completed
  30. Phase 1 Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia Completed
  31. Phase 1 Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Completed
  32. Phase 1 Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies Completed
  33. Phase 1 APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies Completed

Showing the 39 most-cited and recently-updated of 39 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life
Oncology Meta-analysis
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life New combinations show promise for older adults with myeloid leukemia
This systematic review and meta-analysis of 47 studies evaluated treatments for older adults with AML ineligible for conventional chemothera…
Combining specific drugs like venetoclax with other treatments may improve survival and quality of life for older adults with acute myeloid …
Jun 12, 2026
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML
Hematology RCT
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML Trial shows venetoclax combined with chemotherapy for AML
This clinical trial of 259 newly diagnosed patients with acute myeloid leukemia found a 90.3% composite complete remission rate using a 7-da…
A new clinical trial shows that a short 7-day course of venetoclax combined with chemotherapy can achieve high remission rates in AML patien…
Jun 8, 2026
HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis
Hematology Meta-analysis
HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis Combination therapy shows response in relapsed leukemia
This systematic review and meta-analysis of 2289 adults with relapsed/refractory acute myeloid leukemia found that hypomethylating agents pl…
For adults with relapsed leukemia, combining two drugs led to a 50% response rate, offering a potential new option for a tough situation.
Jun 1, 2026
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Infectious Disease Meta-analysis
Meta-analysis of double-expressor lymphoma prognoses and novel therapies Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Frontiers May 22, 2026
Ven-Chi-Dec Regimen Induces Remission in Refractory Hodgkin Lymphoma
Allergy & Immunology Sys. Review
Ven-Chi-Dec Regimen Induces Remission in Refractory Hodgkin Lymphoma Venetoclax combo shows promise for relapsed Hodgkin lymphoma
A 26-year-old with relapsed/refractory classical Hodgkin lymphoma achieved complete metabolic remission after 6 cycles of venetoclax, chidam…
A 26-year-old man with relapsed Hodgkin lymphoma achieved complete remission after a novel three-drug regimen, with no significant side effe…
Frontiers May 15, 2026
Case report and review of TTMV::RARA-positive APL with spinal cord compression in a child
Orthopedics & Sports Medicine Meta-analysis
Case report and review of TTMV::RARA-positive APL with spinal cord compression in a child Doctors treated a boy with rare leukemia and spinal pressure using special drugs
This is a case report with a systematic review of 11 published cases of TTMV::RARA-positive acute promyelocytic leukemia (APL). The authors …
A nine-year-old boy had rare leukemia and spinal cord pressure. Doctors used specific drugs that helped clear the disease and fix his spine.
Frontiers May 9, 2026
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Oncology RCT
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs.
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Apr 28, 2026
Long-course venetoclax with hypomethylating agents in unfit AML patients shows stable efficacy and MRD prognostic value
Oncology Cohort
Long-course venetoclax with hypomethylating agents in unfit AML patients shows stable efficacy and MRD prognostic value Frail Leukemia Patients See Better Results With New Blood Monitoring
This single-center retrospective analysis evaluated long-course venetoclax combined with hypomethylating agents in unfit AML patients.
A new look at blood tests shows how well frail leukemia patients respond to standard treatment.
Frontiers Apr 21, 2026
Case report and literature review on concurrent t-AML and LNTB treated with chemoimmunotherapy
Oncology Sys. Review
Case report and literature review on concurrent t-AML and LNTB treated with chemoimmunotherapy Two Rare Diseases Strike After Lung Cancer Treatment
This case report and literature review describes the management of a 54-year-old male with locally advanced lung squamous cell carcinoma, th…
A lung cancer patient treated with chemo and immunotherapy developed two rare diseases simultaneously: a new blood cancer and tuberculosis.
Frontiers Apr 16, 2026
Case report of ATRA and VAH regimen in refractory EVI1-positive AML
Oncology Sys. Review
Case report of ATRA and VAH regimen in refractory EVI1-positive AML New hope for tough AML cases
This case report with a brief literature review describes a 42-year-old patient with refractory EVI1-positive AML.
A patient with high-risk AML and the tough EVI1 marker achieved complete remission after failing standard treatments, offering new hope for …
Frontiers Apr 16, 2026
Drug Response Profiling in pediatric ALL yields 68% objective responses and bridges to cellular therapies
Oncology Cohort
Drug Response Profiling in pediatric ALL yields 68% objective responses and bridges to cellular therapies Can a simple test find the right drug to save children with tough leukemia?
A prospective, multicenter Drug Response Profiling registry of 340 children with relapsed or refractory acute lymphoblastic leukemia in 17 E…
A simple test matching leukemia drugs to patient cells helped 68% of children respond to treatment and gave 28 of 42 patients a chance to su…
medRxiv Apr 16, 2026
Meta-analysis finds HMA plus venetoclax yields 66% CR/CRi rate in younger, fit AML patients
Oncology Meta-analysis
Meta-analysis finds HMA plus venetoclax yields 66% CR/CRi rate in younger, fit AML patients Analysis finds promising results for leukemia treatment in younger patients
A meta-analysis of 429 younger, fit AML patients found HMA plus venetoclax yielded a 66% CR/CRi rate and 75% 1-year OS.
Younger acute myeloid leukemia patients treated with a specific drug combination achieved 75% one-year survival and 66% complete remission r…
Apr 5, 2026

All venetoclax Articles